scispace - formally typeset
Journal ArticleDOI

Dose escalation of low molecular weight heparin to manage recurrent venous thromboembolic events despite systemic anticoagulation in cancer patients

Reads0
Chats0
TLDR
Cancer patients with recurrent VTE have a short median survival, and Escalating the dose of LMWH can be effective for treating cases that are resistant to standard, weight‐adjusted doses of LM WH or a VKA.
About
This article is published in Journal of Thrombosis and Haemostasis.The article was published on 2009-05-01. It has received 194 citations till now. The article focuses on the topics: Low molecular weight heparin.

read more

Citations
More filters
Journal ArticleDOI

2014 ESC Guidelines on the diagnosis and management of acute pulmonary embolism

TL;DR: Guidelines summarize and evaluate all available evidence at the time of the writing process, on a particular issue with the aim of assisting health professionals in selecting the best management strategies for an individual patient, with a given condition, taking into account the impact on outcome.
References
More filters
Journal ArticleDOI

Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients: Definitions of major bleeding in clinical studies

TL;DR: A definition of major bleeding in non‐surgical patients was developed that should be applicable to studies with all agents that interfere with hemostasis, including anticoagulants, platelet function inhibitors and fibrinolytic drugs.
Journal ArticleDOI

Definition of major bleeding in clinical investigations of antihemostatic medicinal products in surgical patients.

TL;DR: A definition of major bleeding that should be applicable to all agents that interfere with hemostasis is developed and is to seek approval from the regulatory authorities to enhance its incorporation into future clinical trial protocols.
Journal ArticleDOI

Low-Molecular-Weight Heparin versus a Coumarin for the Prevention of Recurrent Venous Thromboembolism in Patients with Cancer

TL;DR: In patients with cancer and acute venous thromboembolism, dalteparin was more effective than an oral anticoagulant in reducing the risk of recurrent thrombosis without increasing therisk of bleeding.
Journal ArticleDOI

Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study.

TL;DR: Hospital or nursing home confinement, surgery, trauma, malignant neoplasm, chemotherapy, neurologic disease with paresis, central venous catheter or pacemaker, varicose veins, and superficial vein thrombosis are independent and important risk factors for VTE.
Journal ArticleDOI

Antithrombotic therapy for venous thromboembolic disease.

TL;DR: It is shown that patients with symptomatic proximal DVT may benefit from fitted compression stockings for at least 3 months to reduce the incidence of the postthrombotic syndrome, and patients with VTE who receive adequate anticoagulation generally do not die of recurrent disease.
Related Papers (5)